These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22980441)

  • 21. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
    Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
    Muselaers CH; Stillebroer AB; Desar IM; Boers-Sonderen MJ; van Herpen CM; de Weijert MC; Langenhuijsen JF; Oosterwijk E; Leenders WP; Boerman OC; Mulders PF; Oyen WJ
    J Nucl Med; 2014 Feb; 55(2):242-7. PubMed ID: 24396030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
    Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
    Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR).
    Kryza D; Vinceneux A; Bidaux AS; Garin G; Tatu D; Cropet C; Badel JN; Perol D; Giraudet AL
    BMC Cancer; 2024 Feb; 24(1):163. PubMed ID: 38302933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250.
    Hendrickx BW; Punt CJ; Boerman OC; Postema EJ; Oosterwijk E; Mavridu A; Corstens FH; Oyen WJ
    Cancer Biother Radiopharm; 2006 Jun; 21(3):263-8. PubMed ID: 16918303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; Oosterwijk-Wakka JC; Oosterhof GO; Witjes JA; Koenders EB; Oyen WJ; Buijs WC; Debruyne FM; Corstens FH; Oosterwijk E
    J Clin Oncol; 1997 Apr; 15(4):1529-37. PubMed ID: 9193349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.
    Steffens MG; Boerman OC; Oyen WJ; Kniest PH; Witjes JA; Oosterhof GO; van Leenders GJ; Debruyne FM; Corstens FH; Oosterwijk E
    Cancer Res; 1999 Apr; 59(7):1615-9. PubMed ID: 10197637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Ohlsson T; Nilsson R; Tennvall J
    Cancer Biother Radiopharm; 2012 Mar; 27(2):134-40. PubMed ID: 22229635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
    Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
    JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250.
    Pryma DA; O'Donoghue JA; Humm JL; Jungbluth AA; Old LJ; Larson SM; Divgi CR
    J Nucl Med; 2011 Apr; 52(4):535-40. PubMed ID: 21421715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.
    Varga Z; de Mulder P; Kruit W; Hegele A; Hofmann R; Lamers C; Warnaar S; Mala C; Ullrich S; Mulders P
    Folia Biol (Praha); 2003; 49(2):74-7. PubMed ID: 12779016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
    Leibovich BC; Sheinin Y; Lohse CM; Thompson RH; Cheville JC; Zavada J; Kwon ED
    J Clin Oncol; 2007 Oct; 25(30):4757-64. PubMed ID: 17947723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
    Hekman MC; Boerman OC; de Weijert M; Bos DL; Oosterwijk E; Langenhuijsen JF; Mulders PF; Rijpkema M
    Clin Cancer Res; 2016 Sep; 22(18):4634-42. PubMed ID: 27103404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma.
    Oosterwijk-Wakka JC; Boerman OC; Mulders PF; Oosterwijk E
    Int J Mol Sci; 2013 May; 14(6):11402-23. PubMed ID: 23759990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
    Bander NH; Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ
    J Clin Oncol; 2005 Jul; 23(21):4591-601. PubMed ID: 15837970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.